Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Sitagliptin in T2DM
NCT00729326Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Primary completion
- Oct 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in Time-averaged Glucose During a 24 Hour Period at 8 weeks. Started Aug 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00729326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00729326.